Jacob Gottlieb and Stuart Weisbrod are once again collaboration and making plans for the future, after nearly two decades of running separate funds. The two have worked in the past at Merlin BioMed Group, and are once again combining their deep healthcare investment experiences under one roof.
Mr.Weisbroad’s academic accomplishments includes an MBA in Finance earned from Columbia University, as well as an impressive track record in healthcare and biotechnology investment. In 1998, Weisbrod with the aid of the knowledge and experience gained, co-founded the investment management company Merlin, which focused on investment in the healthcare sector.
The team that worked under Weisbrod’s supervision and helped with the growth of Merlin included Jacob Gottlieb, who acted as a manager in the year 2000. He, alongside other portfolio managers helped the company gain major clients, including pension funds and wealthy individuals, and was a key player in making Merlin a success, which resulted in returns of over 100% in both 1999 and 2000, before closing down in 2007.
In the years that followed, Weisbroad created a firm named Iguana Healthcare Partners, with a similar investment strategy as Merlin, while Gottlieb created Visium Asset Management with an initial capital of $300 million, a firm that grew and became a hedge fund worth $8 billion. Despite its massive success Visium came under fire in 2016 when three of its executives have been accused of insider trading, and further charges were brought, against the company’s former CFO and against the company itself. Gottlieb’s record remains clean however, as he has never himself been charged, and is currently working on winding down the company.
Despite the problems that Visium is facing and the work needed to wind down the company, Gottlieb is already carefully planning his next move within his new venture, Altium Capital. Similar to his former company, Altium Capital is also a hedge fund. With this being a new beginning for Gottlieb, the firm’s first investment was a stake in Oramed Pharmaceuticals Inc, as the field of health-care investment is where Gottlieb proved to be very successful in the past. Oramed was founded in 2006, and their most revolutionary product waiting approval is an insulin capsule, which can prove to be a significant change in the lives of people that have diabetes, as it replaces the need of an injection.
The two former colleagues, Weisbrod and Gottlieb, successful financial entrepreneurs, can provide the industry with exiting changes for healthcare investment opportunities.